» Articles » PMID: 32451412

Comparing the Immunogenicity of Glycosidase-directed Resiquimod Prodrugs Mediated by Cancer Cell Metabolism

Overview
Specialty Pharmacology
Date 2020 May 27
PMID 32451412
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We have recently developed an enzyme-directed immunostimulant (EDI) prodrug motif, which is metabolized to active immunostimulant by cancer cells and, following drug efflux, activates nearby immune cells, resulting in immunogenicity. In this study, we synthesized several EDI prodrugs featuring an imidazoquinoline immunostimulant resiquimod (a Toll-like receptor 7/8 agonist) covalently modified with glycosidase enzyme-directing groups selected from substrates of β-glucuronidase, α-mannosidase, or β-galactosidase. We compared the glycosidase-dependent immunogenicity elicited by each EDI in RAW-Blue macrophages following conversion to active immunostimulant by complementary glycosidase. At a cellular level, we examined EDI metabolism across three cancer cell lines (B16 melanoma, TC2 prostate, and 4T1 breast cancer). Comparing the relative immunogenicity elicited by each EDI/cancer cell combination, we found that B16 cells produced the highest EDI prodrug immunogenicity, achieving >95% of that elicited by unmodified resiquimod, followed by TC2 and 4T1 cells (40% and 30%, respectively). Immunogenicity elicited was comparable for a given cell type and independent of the glycosidase substrate in the EDIs or differences in functional glycosidase activity between cell lines. Measuring drug efflux of the immunostimulant payload and efflux protein expression revealed that EDI/cancer cell-mediated immunogenicity was governed by efflux potential of the cancer cells. We determined that, following EDI conversion, immunostimulant efflux occurred through both P-glycoprotein-dependent and P-glycoprotein-independent transport mechanisms. Overall, this study highlights the broad ability of EDIs to couple immunogenicity to the metabolism of many cancers that exhibit drug efflux and suggests that designing future generations of EDIs with immunostimulant payloads that are optimized for drug efflux could be particularly beneficial.

Citing Articles

Real-time fluorescent monitoring of phase I xenobiotic-metabolizing enzymes.

Iqbal H, Ilyas K, Akash M, Rehman K, Hussain A, Iqbal J RSC Adv. 2024; 14(13):8837-8870.

PMID: 38495994 PMC: 10941266. DOI: 10.1039/d4ra00127c.


Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.

He L, Zhang M, Cox M, Zhang Q, Donnell A, Zhang Y ACS Med Chem Lett. 2024; 15(2):189-196.

PMID: 38352849 PMC: 10860188. DOI: 10.1021/acsmedchemlett.3c00456.


Tethered Indoxyl-Glucuronides for Enzymatically Triggered Cross-Linking.

Son J, Wu Z, Dou J, Fujita H, Cao P, Liu Q Molecules. 2023; 28(10).

PMID: 37241884 PMC: 10223988. DOI: 10.3390/molecules28104143.


Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.

Li J, Huang L, Zhou H, Shan Y, Chen F, Lehto V Acta Pharmacol Sin. 2022; 43(11):2749-2758.

PMID: 35484402 PMC: 9622913. DOI: 10.1038/s41401-022-00910-w.


Acquired Drug Resistance Enhances Imidazoquinoline Efflux by P-Glycoprotein.

Pulukuri A, Burt A, Opp L, McDowell C, Davaritouchaee M, Nielsen A Pharmaceuticals (Basel). 2021; 14(12).

PMID: 34959691 PMC: 8705394. DOI: 10.3390/ph14121292.


References
1.
MAUGER A, Burke P, Somani H, Friedlos F, Knox R . Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem. 1994; 37(21):3452-8. DOI: 10.1021/jm00047a002. View

2.
Florent J, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson J . Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J Med Chem. 1998; 41(19):3572-81. DOI: 10.1021/jm970589l. View

3.
Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B . Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998; 58(6):1195-201. View

4.
Wei M, Tamiya T, Rhee R, Breakefield X, Chiocca E . Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clin Cancer Res. 1995; 1(10):1171-7. View

5.
Sun Y, Patel A, Kumar P, Chen Z . Role of ABC transporters in cancer chemotherapy. Chin J Cancer. 2012; 31(2):51-7. PMC: 3777472. DOI: 10.5732/cjc.011.10466. View